SomnoMed Limited reported sales results for the third quarter of 2019. The company announced that its core revenues grew by 9% in the third quarter compared to the prior year, reaching $14.3 million for the three month period.

The company expected the company will finish the fiscal year 2019 in line with revenue and EBITDA guidance as adjusted for the S3 write down as disclosed in March 2019.